Is Enasidenib available in China?

Enasidenib, which targets IDH2, was approved by the U.S. Food and Drug Administration (FDA) in 2017 for the treatment of adult patients with relapsed or refractory AML who have IDH2 mutations detected by an FDA-approved test. EnsidipineThe original drug is not currently on the market in China, so this drug is not yet sold in domestic hospitals or pharmacies.

For patients with relapsed or refractory AML who carryIDH2 mutations,ensidipine is a new treatment option. Although not directly comparable to other therapies in the relapsed or refractory setting, ensidipine may provide response, establish or maintain transfusion independence, allow transition to hematopoietic stem cell transplantation, and/or improve survival in heavily pretreated patients. The potential efficacy of ensidipine is specific to patients with IDH2 mutations; a number of testing strategies are available, including FDA-approved polymerase chain reaction-based companion diagnostic tests. It is also important that physicians be aware of the potential adverse effects of ensidipine use. The main serious adverse effect is differentiation syndrome.

The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic ensidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*30 tablets produced by a Laos pharmaceutical factory may be more than 2,000 yuan per box (the price may fluctuate due to the exchange rate). Its pharmaceutical ingredients are basically the same as those of the original drugs sold abroad. For more information on overseas drug prices and specific information, please consult Yaode Medical Consultant.